84 related articles for article (PubMed ID: 19423214)
41. New tools to monitor the impact of viral infection on the alloreactive T-cell repertoire.
D'Orsogna LJ; Amir AL; Zoet YM; van der Meer-Prins PM; van der Slik AR; Kester MG; Heemskerk MH; Doxiadis II; Roelen DL; Claas FH
Tissue Antigens; 2009 Oct; 74(4):290-7. PubMed ID: 19624615
[TBL] [Abstract][Full Text] [Related]
42. Rational optimization of tumor epitopes using in silico analysis-assisted substitution of TCR contact residues.
Shang X; Wang L; Niu W; Meng G; Fu X; Ni B; Lin Z; Yang Z; Chen X; Wu Y
Eur J Immunol; 2009 Aug; 39(8):2248-58. PubMed ID: 19593772
[TBL] [Abstract][Full Text] [Related]
43. CD8+ T-cell responses to tumor-associated antigens correlate with superior relapse-free survival after allo-SCT.
Kapp M; Stevanović S; Fick K; Tan SM; Loeffler J; Opitz A; Tonn T; Stuhler G; Einsele H; Grigoleit GU
Bone Marrow Transplant; 2009 Mar; 43(5):399-410. PubMed ID: 19139738
[TBL] [Abstract][Full Text] [Related]
44. Human leukocyte antigen-G protein expression is an unfavorable prognostic predictor of hepatocellular carcinoma following curative resection.
Cai MY; Xu YF; Qiu SJ; Ju MJ; Gao Q; Li YW; Zhang BH; Zhou J; Fan J
Clin Cancer Res; 2009 Jul; 15(14):4686-93. PubMed ID: 19584149
[TBL] [Abstract][Full Text] [Related]
45. [Cell-mediated immunity in esophageal cancer patients--effect of "109" crude extracts on the cytotoxic effect of lymphocytes from esophageal cancer patients (author's transl)].
Peng RL; Wang DB
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1980 Sep; 2(3):201-3. PubMed ID: 6451323
[No Abstract] [Full Text] [Related]
46. Genetically attenuated parasite vaccines induce contact-dependent CD8+ T cell killing of Plasmodium yoelii liver stage-infected hepatocytes.
Trimnell A; Takagi A; Gupta M; Richie TL; Kappe SH; Wang R
J Immunol; 2009 Nov; 183(9):5870-8. PubMed ID: 19812194
[TBL] [Abstract][Full Text] [Related]
47. Cytotoxic T cell immunity against the non-immunogenic, murine, hepatocellular carcinoma Hepa1-6 is directed towards the novel alternative form of macrophage colony stimulating factor.
Ge L; Zhang JG; Samathanam CA; Delgado C; Tarbiyat-Boldaji M; Dan Q; Hoa N; Nguyen TV; Alipanah R; Pham JT; Sanchez R; Wepsic HT; Morgan TR; Jadus MR
Cell Immunol; 2009; 259(2):117-27. PubMed ID: 19615673
[TBL] [Abstract][Full Text] [Related]
48. IFN-gamma promotes generation of IL-10 secreting CD4+ T cells that suppress generation of CD8 responses in an antigen-experienced host.
Liu XS; Leerberg J; MacDonald K; Leggatt GR; Frazer IH
J Immunol; 2009 Jul; 183(1):51-8. PubMed ID: 19535638
[TBL] [Abstract][Full Text] [Related]
49. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity.
Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ
J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947
[TBL] [Abstract][Full Text] [Related]
50. MMP11: a novel target antigen for cancer immunotherapy.
Peruzzi D; Mori F; Conforti A; Lazzaro D; De Rinaldis E; Ciliberto G; La Monica N; Aurisicchio L
Clin Cancer Res; 2009 Jun; 15(12):4104-13. PubMed ID: 19509157
[TBL] [Abstract][Full Text] [Related]
51. HLA-promiscuous Th1-cell reactivity of MPT64 (Rv1980c), a major secreted antigen of Mycobacterium tuberculosis, in healthy subjects.
Mustafa AS
Med Princ Pract; 2009; 18(5):385-92. PubMed ID: 19648762
[TBL] [Abstract][Full Text] [Related]
52. Allogeneic GM-CSF-secreting tumor cell immunotherapies generate potent anti-tumor responses comparable to autologous tumor cell immunotherapies.
Li B; Simmons A; Du T; Lin C; Moskalenko M; Gonzalez-Edick M; VanRoey M; Jooss K
Clin Immunol; 2009 Nov; 133(2):184-97. PubMed ID: 19664962
[TBL] [Abstract][Full Text] [Related]
53. A novel mouse model for evaluation and prediction of HLA-A2-restricted CEA cancer vaccine responses.
Conforti A; Peruzzi D; Giannetti P; Biondo A; Ciliberto G; La Monica N; Aurisicchio L
J Immunother; 2009 Sep; 32(7):744-54. PubMed ID: 19561534
[TBL] [Abstract][Full Text] [Related]
54. Processing in the endoplasmic reticulum generates an epitope on the insulin A chain that stimulates diabetogenic CD8 T cell responses.
Brosi H; Reiser M; Rajasalu T; Spyrantis A; Oswald F; Boehm BO; Schirmbeck R
J Immunol; 2009 Dec; 183(11):7187-95. PubMed ID: 19890053
[TBL] [Abstract][Full Text] [Related]
55. [Studies on esophageal cancer-associated antigen immunogenicity and its localization in cancer cells].
Chen YF; Tan J; Zhai H
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 1985 Aug; 7(4):279-84. PubMed ID: 2939989
[No Abstract] [Full Text] [Related]
56. CMV-specific TCR-transgenic T cells for immunotherapy.
Schub A; Schuster IG; Hammerschmidt W; Moosmann A
J Immunol; 2009 Nov; 183(10):6819-30. PubMed ID: 19864595
[TBL] [Abstract][Full Text] [Related]
57. The proteasome inhibitor bortezomib enhances the susceptibility to viral infection.
Basler M; Lauer C; Beck U; Groettrup M
J Immunol; 2009 Nov; 183(10):6145-50. PubMed ID: 19841190
[TBL] [Abstract][Full Text] [Related]
58. IL-17-producing CD8+ T lymphocytes from psoriasis skin plaques are cytotoxic effector cells that secrete Th17-related cytokines.
Ortega C; Fernández-A S; Carrillo JM; Romero P; Molina IJ; Moreno JC; Santamaría M
J Leukoc Biol; 2009 Aug; 86(2):435-43. PubMed ID: 19487306
[TBL] [Abstract][Full Text] [Related]
59. Identification of HLA class II H5N1 hemagglutinin epitopes following subvirion influenza A (H5N1) vaccination.
Zinckgraf JW; Sposato M; Zielinski V; Powell D; Treanor JJ; von Hofe E
Vaccine; 2009 Aug; 27(39):5393-401. PubMed ID: 19596415
[TBL] [Abstract][Full Text] [Related]
60. Identification of a novel epitope derived from CML66 that is recognized by anti-leukaemia cytotoxic T lymphocytes.
Suemori K; Fujiwara H; Ochi T; Azuma T; Yamanouchi J; Narumi H; Yakushijin Y; Hato T; Yasukawa M
Br J Haematol; 2009 Jun; 146(1):115-8. PubMed ID: 19388930
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
